Insulet will not receive any proceeds from the sale of shares by the selling stockholders. Insulet has granted to the underwriters an option to purchase up to 734,759 shares of its common stock at the public offering price to cover any over-allotments.
JP Morgan Securities and Merrill Lynch, Pierce, Fenner & Smith are acting as joint book-running managers, and Leerink Swann, Thomas Weisel Partners and Canaccord Adams are acting as co-managers for the offering.